Effects of Caffeic Acid Phenethyl Ester (CAPE) on Hepatopulmonary Syndrome

Basit Öğe Kaydı
dc.authoridAteş, Burhan/0000-0001-6080-229X
dc.authoridCiftci, Ilhan/0000-0001-9080-4480
dc.authoridCakir, Murat/0000-0001-8789-8199
dc.authorwosidAteş, Burhan/AAA-3730-2021
dc.authorwosidCiftci, Ilhan/GNP-4605-2022
dc.authorwosidTurkyilmaz, Serdar/AAL-8606-2021
dc.authorwosidCakir, Murat/A-7170-2018
dc.contributor.authorTekin, Ahmet
dc.contributor.authorTurkyilmaz, Serdar
dc.contributor.authorKucukkartallar, Tevfik
dc.contributor.authorCakir, Murat
dc.contributor.authorYilmaz, Huseyin
dc.contributor.authorEsen, Hasan
dc.contributor.authorAtes, Burhan
dc.date.accessioned2024-08-04T20:35:41Z
dc.date.available2024-08-04T20:35:41Z
dc.date.issued2011
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe aim of this study was to investigate the effects of caffeic acid phenethyl ester (CAPE) on inflammatory and related histopathological changes in the lung and liver in experimental hepatopulmonary syndrome (HPS) model. Forty Sprague Dawley rats were used in this study. The animals were divided into four groups of ten rats each. Group 1 and 2 was subjected the common bile duct (CBD) but not ligated, Group 3; (cirrhosis + saline): the CBD was ligated and was given intraperitoneal saline infusion treatment during 5 weeks. Group 4; (cirrhosis + CAPE): the CBD was ligated and was given intraperitoneal CAPE infusion treatment during 5 weeks. A 5-week waiting period was observed for the development of cirrhosis and the rats' lungs and liver were taken for histopathological examination. The induction of HPS resulted in a significant increase in serum bilurubin, AST, ALT, and NO levels, and decrease PO2 and O-2 saturation. The use of CAPE significant decrease these parameters. Histopathological examination revealed less congestion, portal inflammation, and nodular formations of the liver, and less congestion, emphysematous and inflammatory changes and smallest perialviolar vascular diameters, in the lung in the cirrhosis + CAPE groups than in the other groups. CAPE treatment may be a potential approach for the treatment of hepatopulmonary syndrome in the future.en_US
dc.identifier.doi10.1007/s10753-010-9270-8
dc.identifier.endpage619en_US
dc.identifier.issn0360-3997
dc.identifier.issn1573-2576
dc.identifier.issue6en_US
dc.identifier.pmid21046212en_US
dc.identifier.scopus2-s2.0-82955246790en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage614en_US
dc.identifier.urihttps://doi.org/10.1007/s10753-010-9270-8
dc.identifier.urihttps://hdl.handle.net/11616/95504
dc.identifier.volume34en_US
dc.identifier.wosWOS:000297198400013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer/Plenum Publishersen_US
dc.relation.ispartofInflammationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcirrhosisen_US
dc.subjecthepatopulmonary syndromeen_US
dc.subjectratsen_US
dc.subjectCAPEen_US
dc.titleEffects of Caffeic Acid Phenethyl Ester (CAPE) on Hepatopulmonary Syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu